Neurobiogen Co., Ltd

4:30 PM - 4:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
NEUROBIOGEN prioritizes its research and development efforts to develop innovative new medicine to treat patients who suffer from degenerative brain diseases. Monoamine oxidase–B (MAO-B) has recently emerged as a potential therapeutic target for Alzheimer’s disease because of its association with aberrant gamma-aminobutyric acid production in reactive astrocytes. Al though short-term treatment with irreversible MAO-B inhibitors, such as selegiline, improves cognitive deficits in AD patients, long-term treatments have shown disappointing results. We have developed a potent, highly selective, and reversible MAO-B inhibitor, KDS2010, which overcomes the disadvantages of the irreversible MAO-B inhibitor. Long term treatment with KDS2010 does not induce compensatory mechanisms, thereby significantly attenuating in creased astrocytic GABA levels and astrogliosis, enhancing synaptic transmission, and rescuing learning and memory impairments. Phase1 clinical trial is in progress since Sep2022.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
September in 2019
Main Therapeutic Focus:
Lead Product in Development:
KDS2010 (Selective reversible MAO-B inhibitor)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Institute for Basic Science, Center for Cognition and Sociality